Author(s): Feriozzi S
Abstract Share this page
Abstract The treatment of immune-mediated kidney disease is based on steroids and immunosuppressive drugs that interfere with the immune processes. These groups of drugs have led to significant treatment results. However, their use is not always associated with an improvement of the clinical picture and severe side effects are frequent. Recently, a new group of drugs characterized by a more restricted mechanism of action has been proposed, namely monoclonal antibodies directed against certain cellular components or molecules of inflammation. The anti-CD20 monoclonal antibody Rituximab is the most widely used in immune-mediated kidney disease, but also others, for example eculizimab (anti C5b-9), have emerged in clinical practice. The aim of this paper is to explain the rationale behind the use of these drugs starting from the pathogenetic mechanisms of immune-mediated kidney disease, to summarize their clinical use, and to raise the issue of their safety in clinical practice.
This article was published in G Ital Nefrol
and referenced in Journal of Nephrology & Therapeutics